Eton Pharmaceuticals reported a 73% increase in Q1 2026 product sales to $24.3 million, driven by strong growth across its rare disease portfolio and new product launches including DESMODA and HEMANGEOL. The company raised its full-year 2026 revenue guidance to over $120 million from $110 million, citing early success with new products and ongoing clinical studies. Eton also advanced its R&D pipeline with clinical trials for ET-700 and label expansion studies, positioning for long-term growth in rare disease treatments.
Borders & Southern Petroleum is progressing discussions with multiple parties to farm out its Darwin oil discovery in the Falkland Islands, amid growing investor interest driven by accelerated development of the Sea Lion oil project. The company owns...
Solana (SOL) has surged more than 24% in the past week and 43% over the last month, reclaiming the $100 price level. Institutional and whale investors, including DeFi Development Corp (DFDV), which added 19,000 SOL to its 2.3 million token holdings, ...
Dunkin' and BARK opened their first official dog drive-thru in Quincy, Massachusetts, on National Dog Day, offering dog treats, limited-edition bandanas, and plush toys inspired by Dunkin's menu. The event supports the Dunkin' Joy in Childhood Founda...
US-listed XRP ETFs attracted $28.14 million on August 26, marking the second-largest daily inflow in 2026, led by Bitwise with $13.12 million. Whale wallets accumulated about 460 million XRP tokens, the strongest since February, signaling strong inst...
At Bitcoin Asia 2026 in Hong Kong, former Binance CEO Changpeng Zhao predicted Bitcoin will overtake gold's significance during the next bull market cycle. While gold's market cap is about $32.4 trillion, Bitcoin currently holds $1.6 trillion, with Z...
